Eurofins Scientific (ERFSF) 262.7000 $ERFSF
Global Oligonucleotide Synthesis (Equipment, Reagents & Synthesized Oligonucleotides) Market 2014-2019 - Product & Services, End-User , Application Analysis
M2 - Fri Sep 05, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3xc5t/oligonucleotide) has announced the addition of the "Oligonucleotide Synthesis Market by Product & Services, End-User , Application - Global Forecast to 2019" report to their offering. The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019. Oligonucleotide synthesis has a vast number of applications in nucleic acid array-based technologies, library preparations, next-generation sequencing methods, genomics, nucleic acid-based detection, cell cultures, diagnostics, therapeutics, human identity testing, cloning and genetic engineering, and synthetic biology, among others. Apart from the growing applications of oligos,increasing R&D expenditure in pharmaceutical and biotechnology companies, the evolving significance of RNA-interference oligos in therapeutics and diagnostics, increasing venture capitalist and governmental funding and support, and rapid technological innovations are other factors driving this market's growth. The relatively-untapped Asia-Pacificmarket,and the growth in magnitude of R&D activities in the region,has opened an array of opportunities for players in the oligonucleotide synthesis market. However, regulatory barriers, especially for therapeutic oligos, and downward pricing pressure are the major factors restraining the growth of this market. By products and services, the market is broadly segmented into equipment, reagents, and synthesized oligonucleotides. Among these segments, the synthesized oligonucleotides market segment is expected to register the highest growth rate during the forecast period, owing to the increasing number of applications of synthesized oligonucleotides in research, diagnostics and therapeutics, and a growing demand for custom oligos. The market, by applications, is classified into diagnostics, research, and therapeutics. Research applications are further segmented into PCR, qPCR, sequencing, gene synthesis, and others. The therapeutics market is further segmented into DNA/antisense oligos, RNAi, aptamers, and others. In terms of applications, the research segment commanded the largest share in 2014, while the diagnostics segment is expected to be the fastest-growing segment in the oligonucleotide synthesis market. The therapeutics segment is gaining increasing importance with growing RNAi applications. However, stringent regulatory requirements pose a major challenge for this market. By end users, the market is segmented into academic research institutes, pharmaceutical and biotech firms, and diagnostic labs. Academic research institutes accounted for the largest share of the market in 2014; however, diagnostic laboratories are expected to be the fastest-growing end user segment during the forecast period, owing to growthin the molecular diagnostics field. Scope of the Report By Products & Services - Equipment - Reagents - Synthesized Oligonucleotides By Product Type - Primers - Probes - Intermediate-Scale Synthesis - Large-Scale Synthesis By Service Type - Pre-designed Oligos - Custom Oligos By Application Diagnostics Research - PCR - QPCR - Sequencing - Gene Synthesis - Others Therapeutics - DNA/Antisense Oligos - RNAi Oligos - Aptamer Oligos - Others By End User - Academic Research Institutes - Diagnostic Laboratories - Pharmaceutical & Biotechnology Companies - Others Companies Mentioned - Bioautomation Corporation - Biosearch Technologies, Inc. - Eurofins Genomics (A Subsidiary of Eurofins Scientific Group) - Eurogentec (A Subsidiary of Kaneka Corporation) - GE Healthcare (A Subsidiary of General Electric Company) - Genedesign, Inc. - Integrated Dna Technologies - Sigma-Aldrich Corporation - Trilink Biotechnologies, Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/c3...nucleotide
Ampersand Sells ViraCor-IBT To Eurofins For $255 Million
PR Newswire - Tue Jul 01, 8:00AM CDT
Ampersand Capital Partners has completed the sale of majority owned portfolio company ViraCor-IBT Laboratories ("VIBT" or "ViraCor"
to Eurofins Scientific for $255 million. VIBT is a premier specialty testing laboratory, providing complex, high-value diagnostic tests to 550 institutional clients and more than 4,000 affiliated clinicians across the US with an emphasis on the transplant market. The Company will continue to be known as ViraCor-IBT, operating from its large, state-of-the art facility in the Kansas City area and its satellite laboratory in California.
Eurofins Brings Together the Expertise of MWG Operon and Medigenomix under a New Global Brand, Eurofins Genomics, to Provide Seamless Best-in-Class Genomics Services Worldwide
Business Wire - Wed Apr 02, 12:30AM CDT
Regulatory News:
Global DNA Sequencing Equipment and Services Market 2012-2016
M2 - Tue Jan 14, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdznf/global_dna) has announced the addition of the "Global DNA Sequencing Equipment and Services Market 2012-2016" report to their offering. One of the main trends witnessed in the Global DNA Sequencing Equipment and Services market is increase in number of DNA sequencing projects. The Global DNA Sequencing Equipment and Services market has recently witnessed a significant increase in the number of projects funded by the leading vendors. For instance, Illumina and Partners HealthCare System Inc. announced a strategic alliance in September 2012, in order to offer infrastructure and networking tools for the interpretation and reporting process on genetic sequencing data. Moreover, Hoffmann-La Roche Ltd. and SoftGenetics LLC signed a co-promotion agreement in May 2012 for a new sequencing software tool. Roche and PerkinElmer Inc. announced a new supply agreement in May 2011 for the distribution of the NimbleGen CGX microarray workflow. In addition, Pacific Biosciences announced collaboration in July 2012, with Imec, a Belgium-based nanoelectronics research center focusing on the improvement of innovative microchips for multiplexed single-molecule genetic analysis. Key questions answered in this report: - What will the market size be in 2016 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Accelrys - Agilent Technologies - BGI - Biotique Systems - DNA Electronics - DNASTAR - DNAVision - DNAnexus - Danaher Corp. - Eurofins Scientific - Fluidigm Corp. - Foundation Medicine - Good Start Genetics - HelicosBioSciences - IBM Corp. - Illumina - IntegenX - Knome - Laboratory Corp. of America Holdings - Life Technologies - Macrogen - Oxford Nanopore Technologies - PerkinElmer - QIAGEN - RainDance Technologies - Sequenom - Siemens Healthcare - Source BioScience - TheragenEtex For more information visit http://www.researchandmarkets.com/research/wvdznf/global_dna
Bruker Corporation Announces the Appointment of Dr. Gilles Martin to its Board of Directors
Business Wire - Mon Jan 13, 6:00AM CST
Bruker Corporation (NASDAQ:BRKR) announced the election of Dr. Gilles Martin to its Board of Directors, effective as of today.
Testing Laboratories - Global Strategic Business Report
M2 - Thu Feb 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/fwt2rl/testing) has announced the addition of the "Testing Laboratories - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testing Laboratories in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Introduction To Testing Laboratories 3. Insight Into Select Testing Laboratories Services 4. Product/Service Launches 5. Recent Industry Activity 6. Strategic Corporate Developments
Food Safety Testing - Global Strategic Business Report
M2 - Fri Dec 21, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/6hs4rq/food_safety) has announced the addition of the "Food Safety Testing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Food Safety Testing in US$ Million by the following Product Segments: Pathogens Testing, Pesticide Testing, GMO Testing, and Other Testing. The End-Use markets also analyzed in the report include Processed Food, Dairy, Meat, and Others (includes Fruits, Vegetables, and Juices). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 112 companies including many key and niche players such as 3M Company, BioControl Systems, Inc., bioM?rieux SA, AES Chemunex SA, Biolog, Inc., Celsis International Ltd., Charm Sciences, Inc., DuPont Qualicon, Inc., FOSS A/S, Eurofins GeneScan Europe AG, Genetic
Global Oligonucleotide Synthesis (Equipment, Reagents & Synthesized Oligonucleotides) Market 2014-2019 - Product & Services, End-User , Application Analysis
M2 - Fri Sep 05, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3xc5t/oligonucleotide) has announced the addition of the "Oligonucleotide Synthesis Market by Product & Services, End-User , Application - Global Forecast to 2019" report to their offering. The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019. Oligonucleotide synthesis has a vast number of applications in nucleic acid array-based technologies, library preparations, next-generation sequencing methods, genomics, nucleic acid-based detection, cell cultures, diagnostics, therapeutics, human identity testing, cloning and genetic engineering, and synthetic biology, among others. Apart from the growing applications of oligos,increasing R&D expenditure in pharmaceutical and biotechnology companies, the evolving significance of RNA-interference oligos in therapeutics and diagnostics, increasing venture capitalist and governmental funding and support, and rapid technological innovations are other factors driving this market's growth. The relatively-untapped Asia-Pacificmarket,and the growth in magnitude of R&D activities in the region,has opened an array of opportunities for players in the oligonucleotide synthesis market. However, regulatory barriers, especially for therapeutic oligos, and downward pricing pressure are the major factors restraining the growth of this market. By products and services, the market is broadly segmented into equipment, reagents, and synthesized oligonucleotides. Among these segments, the synthesized oligonucleotides market segment is expected to register the highest growth rate during the forecast period, owing to the increasing number of applications of synthesized oligonucleotides in research, diagnostics and therapeutics, and a growing demand for custom oligos. The market, by applications, is classified into diagnostics, research, and therapeutics. Research applications are further segmented into PCR, qPCR, sequencing, gene synthesis, and others. The therapeutics market is further segmented into DNA/antisense oligos, RNAi, aptamers, and others. In terms of applications, the research segment commanded the largest share in 2014, while the diagnostics segment is expected to be the fastest-growing segment in the oligonucleotide synthesis market. The therapeutics segment is gaining increasing importance with growing RNAi applications. However, stringent regulatory requirements pose a major challenge for this market. By end users, the market is segmented into academic research institutes, pharmaceutical and biotech firms, and diagnostic labs. Academic research institutes accounted for the largest share of the market in 2014; however, diagnostic laboratories are expected to be the fastest-growing end user segment during the forecast period, owing to growthin the molecular diagnostics field. Scope of the Report By Products & Services - Equipment - Reagents - Synthesized Oligonucleotides By Product Type - Primers - Probes - Intermediate-Scale Synthesis - Large-Scale Synthesis By Service Type - Pre-designed Oligos - Custom Oligos By Application Diagnostics Research - PCR - QPCR - Sequencing - Gene Synthesis - Others Therapeutics - DNA/Antisense Oligos - RNAi Oligos - Aptamer Oligos - Others By End User - Academic Research Institutes - Diagnostic Laboratories - Pharmaceutical & Biotechnology Companies - Others Companies Mentioned - Bioautomation Corporation - Biosearch Technologies, Inc. - Eurofins Genomics (A Subsidiary of Eurofins Scientific Group) - Eurogentec (A Subsidiary of Kaneka Corporation) - GE Healthcare (A Subsidiary of General Electric Company) - Genedesign, Inc. - Integrated Dna Technologies - Sigma-Aldrich Corporation - Trilink Biotechnologies, Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/c3...nucleotide
Ampersand Sells ViraCor-IBT To Eurofins For $255 Million
PR Newswire - Tue Jul 01, 8:00AM CDT
Ampersand Capital Partners has completed the sale of majority owned portfolio company ViraCor-IBT Laboratories ("VIBT" or "ViraCor"
to Eurofins Scientific for $255 million. VIBT is a premier specialty testing laboratory, providing complex, high-value diagnostic tests to 550 institutional clients and more than 4,000 affiliated clinicians across the US with an emphasis on the transplant market. The Company will continue to be known as ViraCor-IBT, operating from its large, state-of-the art facility in the Kansas City area and its satellite laboratory in California. Eurofins Brings Together the Expertise of MWG Operon and Medigenomix under a New Global Brand, Eurofins Genomics, to Provide Seamless Best-in-Class Genomics Services Worldwide
Business Wire - Wed Apr 02, 12:30AM CDT
Regulatory News:
Global DNA Sequencing Equipment and Services Market 2012-2016
M2 - Tue Jan 14, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdznf/global_dna) has announced the addition of the "Global DNA Sequencing Equipment and Services Market 2012-2016" report to their offering. One of the main trends witnessed in the Global DNA Sequencing Equipment and Services market is increase in number of DNA sequencing projects. The Global DNA Sequencing Equipment and Services market has recently witnessed a significant increase in the number of projects funded by the leading vendors. For instance, Illumina and Partners HealthCare System Inc. announced a strategic alliance in September 2012, in order to offer infrastructure and networking tools for the interpretation and reporting process on genetic sequencing data. Moreover, Hoffmann-La Roche Ltd. and SoftGenetics LLC signed a co-promotion agreement in May 2012 for a new sequencing software tool. Roche and PerkinElmer Inc. announced a new supply agreement in May 2011 for the distribution of the NimbleGen CGX microarray workflow. In addition, Pacific Biosciences announced collaboration in July 2012, with Imec, a Belgium-based nanoelectronics research center focusing on the improvement of innovative microchips for multiplexed single-molecule genetic analysis. Key questions answered in this report: - What will the market size be in 2016 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Accelrys - Agilent Technologies - BGI - Biotique Systems - DNA Electronics - DNASTAR - DNAVision - DNAnexus - Danaher Corp. - Eurofins Scientific - Fluidigm Corp. - Foundation Medicine - Good Start Genetics - HelicosBioSciences - IBM Corp. - Illumina - IntegenX - Knome - Laboratory Corp. of America Holdings - Life Technologies - Macrogen - Oxford Nanopore Technologies - PerkinElmer - QIAGEN - RainDance Technologies - Sequenom - Siemens Healthcare - Source BioScience - TheragenEtex For more information visit http://www.researchandmarkets.com/research/wvdznf/global_dna
Bruker Corporation Announces the Appointment of Dr. Gilles Martin to its Board of Directors
Business Wire - Mon Jan 13, 6:00AM CST
Bruker Corporation (NASDAQ:BRKR) announced the election of Dr. Gilles Martin to its Board of Directors, effective as of today.
Testing Laboratories - Global Strategic Business Report
M2 - Thu Feb 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/fwt2rl/testing) has announced the addition of the "Testing Laboratories - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testing Laboratories in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Introduction To Testing Laboratories 3. Insight Into Select Testing Laboratories Services 4. Product/Service Launches 5. Recent Industry Activity 6. Strategic Corporate Developments
Food Safety Testing - Global Strategic Business Report
M2 - Fri Dec 21, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/6hs4rq/food_safety) has announced the addition of the "Food Safety Testing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Food Safety Testing in US$ Million by the following Product Segments: Pathogens Testing, Pesticide Testing, GMO Testing, and Other Testing. The End-Use markets also analyzed in the report include Processed Food, Dairy, Meat, and Others (includes Fruits, Vegetables, and Juices). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 112 companies including many key and niche players such as 3M Company, BioControl Systems, Inc., bioM?rieux SA, AES Chemunex SA, Biolog, Inc., Celsis International Ltd., Charm Sciences, Inc., DuPont Qualicon, Inc., FOSS A/S, Eurofins GeneScan Europe AG, Genetic
